Brand-Ad-30-6
 IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 2278 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
  Search
 
  
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Article in PDF (274 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

 
  In this article
   References

 Article Access Statistics
    Viewed2011    
    Printed33    
    Emailed0    
    PDF Downloaded119    
    Comments [Add]    

Recommend this journal

 


 
 Table of Contents    
LETTER TO THE EDITOR
Year : 2015  |  Volume : 81  |  Issue : 1  |  Page : 57

Author's Response - The efficacy of azithromycin in pityriasis rosea: A randomized, double-blind, placebo-controlled trial


Department of Dermatology and STD, University College of Medical Sciences and Guru Teg Bahadur Hospital, University of Delhi, Delhi, India

Date of Web Publication6-Jan-2015

Correspondence Address:
Dr. Deepika Pandhi
B 1/1101, Vasant Kunj,Delhi - 110 070
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0378-6323.148573

Rights and Permissions



How to cite this article:
Pandhi D, Verma P, Singal A, Sharma R. Author's Response - The efficacy of azithromycin in pityriasis rosea: A randomized, double-blind, placebo-controlled trial. Indian J Dermatol Venereol Leprol 2015;81:57

How to cite this URL:
Pandhi D, Verma P, Singal A, Sharma R. Author's Response - The efficacy of azithromycin in pityriasis rosea: A randomized, double-blind, placebo-controlled trial. Indian J Dermatol Venereol Leprol [serial online] 2015 [cited 2020 Aug 5];81:57. Available from: http://www.ijdvl.com/text.asp?2015/81/1/57/148573


Sir,

We would like to thank Drago et al. for their interest in our publication. [1] The authors also point out that macrolides including azithromycin are known to have antiinflammatory and immuno-modulatory actions and therefore, their efficacy does not necessarily support bacterial infection (s) or exclude viral infection (s) from being the cause of pityriasis rosea (PR). [2] In 2000, Sharma et al.[3] published a study that showed great success with oral erythromycin in inducing resolution of pityriasis rosea in a group of 45 patients. Similarly, Villarama et al. also found erythromycin to be effective in a randomized double-blind control trial (unpublished). [2] There was a dearth of randomized double-blind control trials of macrolides in pityriasis rosea. Amer et al.[4] reported the only randomized double-blind placebo-controlled published trial in which azithromycin was not found to be effective. Their study comprised only 49 pediatric patients (mean age: 8 years) while the present study comprised a larger sample size of 70 and included patients with a mean age of 23.3 years (range 2-44 years). Further there were 2 other differences: pityriasis rosea was diagnosed by dermatologists and the objective pityriasis rosea severity score (PRSS) was employed in our study. [4] Chuh et al., in their comprehensive systematic review of interventions in pityriasis rosea, had recommended more randomized controlled trials in particular to investigate the efficacy of oral erythromycin or other macrolide antibiotics. [2] Also, it is pertinent to note that there have been several recent published case reports reporting successful treatment of pityriasis rosea with various macrolides including clarithromycin and roxithromycin. [5],[6] The aim of our study was not to find the ideal treatment for pityriasis rosea but to evaluate the efficacy of azithromycin in a double-blind placebo-controlled trial. The negative results obtained by us do not favor the prescription of azithromycin for pityriasis rosea. [1] The excellent results of acyclovir obtained by other workers can also be validated by similar double-blind placebo-controlled trial using a tool such as pityriasis rosea severity score (PRSS) in a large cohort of patients. [6],[7] Finally we concur with the author's statement that as of now no treatment can be recommended on the basis of evidence-based medicine, and pityriasis rosea remains a self-limiting exanthematous disease that probably just needs reassurance of the patient, which significantly was also the concluding statement of our study.

 
  References Top

1.
Pandhi D, Singal A, Verma P, Sharma R. The efficacy of azithromycin in pityriasis rosea: A randomized, double-blind, placebo-controlled trial. Indian J Dermatol Venereol Leprol 2014;80:36-40.  Back to cited text no. 1
[PUBMED]  Medknow Journal  
2.
Chuh AA, Dofitas BL, Comisel G, Reveiz L, Sharma V, Garner SE, et al. Interventions for pityriasis rosea. Cochrane Database Syst Rev 2007. Available from: http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005068/frame.html[Last accessed on 2007 Apr 18].  Back to cited text no. 2
    
3.
Sharma PK, Yadav TP, Gautam RK, Taneja N, Satyanarayana L. Erythromycin in pityriasis rosea: A double-blind, placebo controlled clinical trial. J Am Acad Dermatol 2000;42:241-4.  Back to cited text no. 3
    
4.
Amer A, Fischer H. Azithromycin does not cure pityriasis rosea. Pediatrics 2006;117:1702-5.  Back to cited text no. 4
    
5.
Singh V, Sharma M, Narang T, Madan M. Vesicular palmoplantar pityriasis rosea. Skinmed 2012;10:116-8.  Back to cited text no. 5
    
6.
Ehsani A, Esmaily N, Noormohammadpour P, Toosi S, Hosseinpour A, Hosseini M, et al. The comparison between the efficacy of high dose acyclovir and erythromycin on the period and signs of pityriasis rosea. Indian J Dermatol 2010;55:246-8.  Back to cited text no. 6
[PUBMED]  Medknow Journal  
7.
Drago F, Vecchio F, Rebora A. Use of high-dose acyclovir in pityriasis rosea. J Am Acad Dermatol 2006;54:82-5.  Back to cited text no. 7
    




 

Top
Print this article  Email this article

    

Online since 15th March '04
Published by Wolters Kluwer - Medknow